# US 2025/0319214 A1 · A novel kit for radiopharmaceutical preparation of a radiometal labeled chelate-functionalized targeting conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0319214 A1
- Document ID: US20250319214A1
- Status: Published application
- Kind: A1
- Application number: 18/574,445
- Filed: 2022-06-29
- Published: 2025-10-16
- Earliest claimed: 2021-06-29
- Assignees: Life Molecular Imaging SA
- Applicants: Life Molecular Imaging Ltd.
- Inventors: Marion ZERNA; Hanno SCHIEFERSTEIN; Mathias BERNDT
- Web page: https://patentgrep.com/patent/US20250319214A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- C07B 59/00: Introduction of isotopes of elements into organic compounds {; Labelled organic compounds per se}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 2121/00: Preparations for use in therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprising a chelate-functionalized GRP receptor targeting conjugate comprising i. a chelating moiety ii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, and iii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety, and at least one GRP receptor (GRPr) targeting moiety, at least one non-reducing sugar selected from the group comprising trehalose and sucrose, and at least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.

## Claims

### Claim 1

A lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized targeting conjugates comprising
a chelate-functionalized targeting conjugate comprising
i. a chelating moiety
ii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, and
iii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety,
at least one non-reducing sugar selected from the group comprising trehalose and sucrose, and
at least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.

### Claim 2 (depends on 1)

The kit formulation according to claim 1, wherein the concentration of the non-reducing sugar in said formulation is 10-600 μmol, preferably, 20-500 μmol, more preferably, 50-300 μmol.

### Claim 3 (depends on 1)

The kit formulation according to claim 1, wherein the concentration of said radiostabilizer in the formulation is 1-500 μmol, preferably 5-250 μmol, more preferably 10-100 μmol.

### Claim 4 (depends on 1)

The kit formulation according to claim 1, wherein the amount of ascorbic acid in the formulation is 1-20 mg, more preferably 1-10 mg.

### Claim 5 (depends on 1)

The kit formulation according to claim 1, wherein said chelating moiety is selected from the group comprising TACN, TACN-TM, DTAC, H3NOKA, NODASA, NODAGA, NOTP, NOTPME, PrP9, TRAP, Trappist Pr, NOPO, TETA; Tris(hydroxypyridinone) (THP) and derivatives, chelates open chain such as HBED, DFO or desferrioxamine or desferal, EDTA, 6SS, B6SS, PLED, TAME, YM103; NTP (PRHP)3; the H2dedpa and its derivatives such as H2dedpa-1, 2-H2dedpa, H2dp-bb-NCS, and H2dp-N-NCS; (4,6-Me02sal) 2-BAPEN; and citrate and derivatives thereof.

### Claim 6 (depends on 1)

The kit formulation according to claim 1, wherein the linker is selected from the group comprising a bond, a natural amino acid, an unnatural amino acid, a linear diamine, a cyclic diamine, a linear carboxylic acid, a cyclic carboxylic acid, polyethylene glycol (PEG) and combinations thereof.

### Claim 7 (depends on 1)

The kit formulation according to claim 1, wherein said a GRP receptor (GRPr) targeting molecule comprises peptide sequences selected from the group comprising:
Gln-Trp-Ala-Val-Gly-His,
D-Phe-Gln-Trp-Ala-Val-Gly-His,
Gln-Trp-Ala-Val-Gly-His-Sta,
D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta,
Gln-Trp-Ala-Val-Gly-His-Leuψ(CHOH-CH2)-
(CH2)2-CH3,
D-Phe-Gln-Trp-Ala-Val-Gly-His-Leuψ(CHOH-
CH2)-(CH2)2-CH3,
D-Phe-Gln-Trp-Ala-Val-Gly-His-Leuψ(CH2NH),
Gln-Trp-Ala-Val-Gly-His-Leuψ(CH2NH),
Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2,
or
D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2.

### Claim 8 (depends on 1)

The kit formulation according to claim 1, wherein the formulation for preparation of chelate-functionalized GRP receptor targeting conjugates is labeled with a trivalent radiometal cation or a bivalent radiometal cation.

### Claim 9 (depends on 1)

A method for preparation of a radiometal labeled chelate-functionalized GRP receptor targeting conjugate using said kit formulation according to claim 1, comprising the steps of
mixing a solution of the radiometal with the kit formulation according to claim 1,
optionally, adding at least one labeling buffer or a mixture of labeling buffers, and
complexing the chelate-functionalized GRP receptor targeting conjugate according to claim 1 with the radiometal.

### Claim 10 (depends on 9)

A radiometal labeled chelate-functionalized targeting conjugate obtainable by the method according to claim 9.

### Claim 11 (depends on 10)

A radiopharmaceutical composition comprising the radiometal labeled chelate-functionalized GRP receptor targeting conjugate according to claim 10.

### Claim 12 (depends on 1)

A kit comprising
a vial comprising the lyophilized kit formulation according to claim 1;
a vial or a syringe comprising at least one labelling buffer or a mixture of labelling buffers and/or
a vial or syringe comprising a solution of the radiometal.
